Last reviewed · How we verify

Topical liquid lidocaine

OHSU Knight Cancer Institute · FDA-approved active Small molecule

Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia.

Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia. Used for Oral mucositis pain relief in cancer patients, Localized pain management in cancer care settings.

At a glance

Generic nameTopical liquid lidocaine
SponsorOHSU Knight Cancer Institute
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaOncology (supportive care)
PhaseFDA-approved

Mechanism of action

Lidocaine is a local anesthetic that works by inhibiting sodium influx through sodium-selective channels in the nerve cell membrane, thereby blocking the generation and propagation of action potentials. When applied topically, it numbs the skin and mucous membranes in the area of application. This mechanism makes it useful for reducing pain and discomfort in localized areas, particularly in cancer patients experiencing oral mucositis or other localized pain conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: